Avenue Therapeutics, Inc. (ATXI) Stock Ticker
Market factors today
Unlock the full ATXI picture
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
ATXI stock facts
| Ticker symbol | ATXI |
| Exchange | Other OTC |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.8M |
| CEO | Alexandra MacLean |
| Employees | 1 |
| Headquarters | Bay Harbor Islands, FL, US |
| IPO date | 2017-06-27 |
| Website | www.avenuetx.com |
What you can see for ATXI on Tickr
Live ATXI price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ATXI report.
Rankings
FAQ
What is the ticker symbol for Avenue Therapeutics, Inc.?
The ticker symbol for Avenue Therapeutics, Inc. is ATXI, listed on the Other OTC.
What is ATXI?
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the…